KiromicBioPharma

We are a clinical-stage, fully integrated biotherapeutics company using our proprietary DIAMOND® AI platform to discover and develop cell and gene therapies.

[KiromicBioPharma @KiromicBioPharm]

Exciting news! We begin evaluating Deltacel,
our off-the-shelf Gamma Delta T-cell therapy, in NSCLC. Beverly Hills Cancer Center is the inaugural clinical site, with up to four prestigious sites expected overall. #cart #NSCLC #clinicaltrials
https://t.co/IdCEMbwtdu

[KiromicBioPharma @KiromicBioPharm]

In Q4 2021, Kiromic made critical advancements in R&D, manufacturing, & clinical trial prep. We expect to begin activation of the clinical trial for our first oncology cell therapy candidate by the end of Q4 2022. Read more at https://t.co/iKPkOlMH3d.

[KiromicBioPharma @KiromicBioPharm]

Kiromic BioPharma's April 2022 Corporate Presentation is now live on the investor relations section of our website. Webpage: https://t.co/jifqSOoMw1. Direct download: https://t.co/JDJRVbx2IK.

[KiromicBioPharma @KiromicBioPharm]

Kiromic is laser-focused on our goals. We appointed Pietro Bersani as Interim CEO, Michael Nagel as Chairman, and Frank Tirelli and Karen Reeves MD to the Board. We believe that their knowledge and experience will accelerate our progress in 2022. https://t.co/hQervAU8cN

[KiromicBioPharma @KiromicBioPharm]

The Kiromic team grew this year! We look forward to working with this group of dedicated, diverse, and talented employees in 2022, as we accelerate the discovery and development of cell & gene therapies in #immunooncology and other diseases.

[KiromicBioPharma @KiromicBioPharm]

Kiromic's CEO, Dr. Chiriva-Internati, spoke in October about Allogenic Off the Shelf CAR T Cell Therapy and the possibilities in #solidtumors at the @mnmconferences Next Gen #Immunooncology Congress. Missed it? Here's the full presentation: https://t.co/yBzgSZgh26

[KiromicBioPharma @KiromicBioPharm]

The latest @CGT_Insights Spotlight article, by Kiromic's own experts, details how AI is accelerating translational #celltherapy development and neoantigen discovery, and the resulting promise of rapid advancement of #immunooncology. Read the full article:

[KiromicBioPharma @KiromicBioPharm]

This Thanksgiving, we're thankful for our amazing #Kiromic employees, partners, investors, families and friends. You make it possible for us to keep working toward #allogeneic #celltherapies & #genetherapies for patients with solid tumor cancers. Thank you and Happy Thanksgiving!

[KiromicBioPharma @KiromicBioPharm]

Today, on World Pancreatic Cancer Day, & every day, 1,358 people worldwide are diagnosed with pancreatic cancer. That's why Kiromic works today, & every day, on developing CAR-T cell therapies to target solid cancers like #pancreaticcancer. #ItsAboutTime

[KiromicBioPharma @KiromicBioPharm]

Did you miss Kiromic CEO Dr. Chiriva-Internati today at the Cellular #Immunotherapies for Solid Tumors Summit? He'll be back tomorrow to talk about "Bioinformatics to Identify Optimal #SolidTumor Targets and Improve Antigen Selection." View full agenda: https://t.co/CBlLGWPavh

[KiromicBioPharma @KiromicBioPharm]

Join our CEO, Dr. Maurizio Chiriva-Internati in discussing optimal cells and tumor targeting for #celltherapy during next week's virtual Cellular #Immunotherapies for Solid Tumors 2021 Summit. For more info and full agenda, visit: https://t.co/GnWRMEevDT

[KiromicBioPharma @KiromicBioPharm]

Wednesday, our CEO, Maurizio Chiriva-Internati will be presenting the topic “Allogenic Off the Shelf CAR-T Cell Therapy” at the Next Gen #ImmunoOncology Virtual Congress from @mnmconferences. Learn more here: https://t.co/J5mn2yBUnA #cartcell

[KiromicBioPharma @KiromicBioPharm]

@NMarmot61 Thanks for your interest. You can find the link to the published study on our website at https://t.co/KJgwnlfpsf under BSK01. The publication in Translational Medicine Communications contains details about the clinical study and its results.

[KiromicBioPharma @KiromicBioPharm]

Clinical stage Kiromic BioPharma shares published Phase 1 clinical trial results for KiroVax/BSK01, a cell therapy cancer vaccine candidate for solid tumors. The progression free survival data validates our proprietary DIAMOND AI platform. Read more: https://t.co/N4QQUgNS7x

[KiromicBioPharma @KiromicBioPharm]

Today we announced a new partnership with Gemelli Teaching Hospital IRCCS to accelerate analysis of our first allogeneic #CARTcell clinical trial candidate Alexis ISO-1 in solid tumor cancers. Read more about this strategic #oncology collaboration: https://t.co/8YYbtJFjIs

[KiromicBioPharma @KiromicBioPharm]

https://t.co/2yFx420vHE

[KiromicBioPharma @KiromicBioPharm]

https://t.co/31FijMlU04

[KiromicBioPharma @KiromicBioPharm]

https://t.co/riOfPadUGM

[KiromicBioPharma @KiromicBioPharm]

https://t.co/K6Fm21Pfdp

[KiromicBioPharma @KiromicBioPharm]

https://t.co/uL03wYot3r